FDA.reportPublic FDA data

Xeljanz

RxCUI
1357542
RxNorm name
Xeljanz
Term type
BN
Status
Active
Updated
2026-07-24 06:52:01

RxNorm Status History#

Status
Active
Source
RXNORM
Current
YES
Release start
122012
Active start
122012
Multiple ingredient
NO
Branded
YES

Derived Ingredient Concepts#

Ingredient, RxCUI table
IngredientRxCUI
tofacitinib1357536

Source Vocabulary Codes#

Code type, Value, Category table
Code typeValueCategory
PRESCRIBABLEYATTRIBUTES
RXNAV_STRXeljanzNAMES
RxNorm NameXeljanzNAMES
TTYBNATTRIBUTES
RxCUI1357542CODES
MMSL_CODEBN194456CODES

Drug Classes#

Source, Class ID, Class table
SourceClass IDClassTypeRelationshipDrug concept
ATCL04AFJanus-associated kinase (JAK) inhibitorsATC1-4tofacitinib
FDASPLN0000190858Janus Kinase InhibitorEPChas_epctofacitinib
FDASPLN0000190857Janus Kinase InhibitorsMOAhas_moatofacitinib
MEDRTD010880PiperidinesCHEMhas_ingredienttofacitinib
MEDRTD010880PiperidinesCHEMhas_ingredienttofacitinib citrate
MEDRTD011743PyrimidinesCHEMhas_ingredienttofacitinib
MEDRTD001172Arthritis, RheumatoidDISEASEmay_treattofacitinib
MEDRTD001172Arthritis, RheumatoidDISEASEmay_treattofacitinib citrate
MEDRTN0000190857Janus Kinase InhibitorsMOAhas_moatofacitinib
MEDRTN0000190857Janus Kinase InhibitorsMOAhas_moatofacitinib citrate
MEDRTN0000008656Decreased HematopoiesisPEhas_petofacitinib
MEDRTN0000008656Decreased HematopoiesisPEhas_petofacitinib citrate
MEDRTN0000175550Decreased Immunologic ActivityPEhas_petofacitinib
MEDRTN0000175550Decreased Immunologic ActivityPEhas_petofacitinib citrate

Properties#

Category, Property, Value table
CategoryPropertyValue
ATTRIBUTESBN_CARDINALITYsingle
ATTRIBUTESGENERAL_CARDINALITYSINGLE
ATTRIBUTESPRESCRIBABLEY
ATTRIBUTESRXNAV_HUMAN_DRUGUS
ATTRIBUTESTTYBN
CODESMMSL_CODEBN194456
CODESRxCUI1357542
NAMESRXNAV_STRXeljanz
NAMESRxNorm NameXeljanz
SOURCESSourceMultum MediSource Lexicon